Skip to main content

Market Overview

Moleculin Biotech Stock Is Trading Higher After WP1066 Scores Rare Pediatric Disease Tag For Type Of Brain Tumor

Share:
Moleculin Biotech Stock Is Trading Higher After WP1066 Scores Rare Pediatric Disease Tag For Type Of Brain Tumor
  • The FDA has granted Rare Pediatric Disease Designation to Moleculin Biotech Inc's (NASDAQ: MBRX) WP1066 to treat ependymoma.
  • Ependymoma is a rare type of tumor in the brain or spinal cord and most often occurs in young children.
  • The drug candidate currently received Orphan Drug Designation for WP1066 to treat brain tumors and Rare Pediatric tags for three other pediatric indications.
  • Rare Pediatric Disease designation provides for the issuance of a priority review voucher following FDA approval. The voucher can be used for accelerated approval of a future application or sold to a third party.
  • WP1066 is an immune/transcription modulator capable of directly inhibiting certain key oncogenic transcription factors, including the activated form of a protein known as STAT3.
  • The activated form of STAT3, referred to as p-STAT3, is considered a master regulator of tumor activity. 
  • Price Action: MBRX shares are trading 6.96% higher at $3.87 on the last check Wednesday.
 

Related Articles (MBRX)

View Comments and Join the Discussion!

Posted-In: Brain Tumor BriefsBiotech News Penny Stocks Entrepreneurship FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com